- •Preface
- •Contents
- •1 Extracellular and Intracellular Signaling – a New Approach to Diseases and Treatments
- •1.1 Introduction
- •1.1.1 Linear Model of Drug Receptor Interactions
- •1.1.2 Matrix Model of Drug Receptor Interactions
- •1.2 Experimental Approaches to Disease Treatment
- •1.3 Adipokines and Disease Causation
- •1.4 Questions in Disease Treatment
- •1.5 Toxic Lifestyles and Disease Treatment
- •References
- •2.1 Introduction
- •2.2 Heterogeneity of Adipose Tissue Composition in Relation to Adipokine and Cytokine Secretion
- •2.3 Feedback between FA and the Adipocyte
- •2.6 Metabolic Programming of Autocrine Signaling in Adipose Tissue
- •2.8 Cell Heterogeneity in the Pancreatic Islet
- •2.16 Concluding Remarks
- •Acknowledgements
- •References
- •3 One Receptor for Multiple Pathways: Focus on Leptin Signaling
- •3.1 Leptin
- •3.2 Leptin Receptors
- •3.3 Leptin Receptor Signaling
- •3.3.4 AMPK
- •3.3.5 SOCS3
- •3.4 Leptin Receptor Interactions
- •3.4.1 Apolipoprotein D
- •3.4.2 Sorting Nexin Molecules
- •3.4.3 Diacylglycerol Kinase Zeta
- •3.4.4 Apolipoprotein J
- •References
- •4.1 Introduction
- •4.2 Leptin: A Brief Introduction
- •4.3 Expression of Leptin Receptors in Cardiovascular Tissues
- •4.6 Post Receptor Leptin Signaling
- •4.6.2 Mitogen Activated Protein Kinase Stimulation
- •4.7 Adiponectin
- •4.7.1 Adiponectin and Cardiovascular Disease
- •4.7.2 Adiponectin and Experimental Cardiac Hypertrophy
- •4.8 Resistin
- •4.8.1 Cardiac Actions of Resistin
- •4.8.1.1 Experimental Studies on the Cardiac Actions of Resistin
- •4.9 Apelin
- •4.9.1 Apelin and Heart Disease
- •4.10 Visfatin
- •4.11 Other Novel Adipokines
- •4.12 Summary, Conclusions and Future Directions
- •Acknowledgements
- •References
- •5 Regulation of Muscle Proteostasis via Extramuscular Signals
- •5.1 Basic Protein Synthesis
- •5.2.1 Hormones
- •5.2.1.1 Mechanisms of Action: Glucocorticoids
- •5.2.1.2 Mechanisms of Action: TH (T3)
- •5.2.1.3 Mechanisms of Action: Testosterone
- •5.2.1.4 Mechanisms of Action: Epinephrine
- •5.2.2 Local Factors (Autocrine/Paracrine)
- •5.2.2.1 Mechanisms of Action: Insulin/IGF Spliceoforms
- •5.2.2.2 Mechanisms of Action: Fibroblast Growth Factor (FGF)
- •5.2.2.3 Mechanisms of Action: Myostatin
- •5.2.2.4 Mechanisms of Action: Cytokines
- •5.2.2.5 Mechanisms of Action: Neurotrophins
- •5.2.2.7 Mechanisms of Action: Extracellular Matrix
- •5.2.2.8 Mechanisms of Action: Amino Acids (AA)
- •5.3 Regulation of Muscle Proteostasis in Humans
- •5.3.1 Nutrients as Regulators of Muscle Proteostasis in Man
- •5.3.2 Muscular Activity (i.e. Exercise) as a Regulator of Muscle Proteostasis
- •5.4 Conditions Associated with Alterations in Muscle Proteostasis in Humans
- •5.4.2 Disuse Atrophy
- •5.4.3 Sepsis
- •5.4.4 Burns
- •5.4.5 Cancer Cachexia
- •References
- •6 Contact Normalization: Mechanisms and Pathways to Biomarkers and Chemotherapeutic Targets
- •6.1 Introduction
- •6.2 Contact Normalization
- •6.3 Cadherins
- •6.4 Gap Junctions
- •6.5 Contact Normalization and Tumor Suppressors
- •6.6 Contact Normalization and Tumor Promoters
- •6.7 Conclusions
- •References
- •7.1 Introduction
- •7.2 Background on Migraine Headache
- •7.3 Migraine and Neuropathic Pain
- •7.4 Role of Astrocytes in Pain
- •7.5 Adipokines and Related Extracellular Signalling
- •7.6 The Future of Signaling Research to Migraine
- •Acknowledgements
- •References
- •8.1 Alzheimer’s Disease
- •8.1.2 Target for AD Therapy
- •8.2 AD and Metabolic Dysfunction
- •8.2.1 Impaired Glucose Metabolism
- •8.2.2 Lipid Disorders
- •8.2.3 Obesity
- •8.3 Adipokines
- •8.3.1 Leptin
- •8.3.2 Adiponectin
- •8.3.3 Resistin
- •8.3.4 Visfatin
- •8.3.5 Plasminogen Activator Inhibitor
- •8.3.6 Interleukin-6
- •8.4 Conclusions
- •References
- •9.1 Introduction
- •9.1.1 Structure and Function of Astrocytes
- •9.1.1.1 Morphology
- •9.1.1.2 Astrocyte Functions
- •9.1.2 Responses of Astrocytes to Injury
- •9.1.2.1 Reactive Astrocytosis
- •9.1.2.2 Cell Swelling
- •9.1.2.3 Alzheimer Type II Astrocytosis
- •9.2 Intracellular Signaling System in Reactive Astrocytes
- •9.2.1 Oxidative/Nitrosative Stress (ONS)
- •9.2.2 Protein Kinase C (PKC)
- •9.2.5 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3 Signaling Systems in Astrocyte Swelling
- •9.3.1 Oxidative/Nitrosative Stress (ONS)
- •9.3.2 Cytokines
- •9.3.3 Protein Kinase C (PKC)
- •9.3.5 Protein Kinase G (PKG)
- •9.3.7 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3.10 Ion Channels/Transporters/Exchangers
- •9.4 Conclusions and Perspectives
- •Acknowledgements
- •References
- •10.1 Adipokines, Toxic Lipids and the Aging Brain
- •10.1.1 Toxic Lifestyles, Adipokines and Toxic Lipids
- •10.1.2 Ceramide Toxicity in the Brain
- •10.3 Oxygen Radicals, Hydrogen Peroxide and Cell Death
- •10.4 Gene Transcription and DNA Damage
- •10.5 Conclusions
- •References
- •11.1 Introduction
- •11.2 Cellular Signaling
- •11.2.1 Types of Signaling
- •11.2.2 Membrane Proteins in Signaling
- •11.3 G Protein-Coupled Receptors
- •11.3.1 Structure of GPCRs
- •11.3.1.1 Structure Determination
- •11.3.1.2 Structural Diversity of Current GPCR Structures
- •11.3.1.3 Prediction of GPCR Structure and Ligand Binding
- •11.3.2 GPCR Activation: Conformation Driven Functional Selectivity
- •11.3.2.2 Ligand or Mutation Stabilized Ensemble of GPCR Conformations
- •11.3.2.4 GPCR Dimers and Interaction with Other Proteins
- •11.3.3 Functional Control of GPCRs by Ligands
- •11.3.3.1 Biased Agonism
- •11.3.3.2 Allosteric Ligands and Signal Modulation
- •11.3.4 Challenges in GPCR Targeted Drug Design
- •11.4 Summary and Looking Ahead
- •Acknowledgements
- •References
- •12.1 Introduction
- •12.5.1 Anthocyanins
- •12.5.2 Gallates
- •12.5.3 Quercetin
- •12.5.5 Piperine
- •12.5.6 Gingerol
- •12.5.7 Curcumin
- •12.5.8 Guggulsterone
- •12.6.1 Phytanic Acid
- •12.6.2 Dehydroabietic Acid
- •12.6.3 Geraniol
- •12.7 Agonists of LXR that Reciprocally Inhibit NF-jB
- •12.7.1 Stigmasterol
- •12.7.3 Ergosterol
- •12.8 Conclusion
- •References
- •13.1 Introduction
- •13.2 Selective Dopaminergic Neuronal Death
- •13.3 Signaling Pathways Involved in Selective Dopaminergic Neuronal Death
- •13.3.1 Initiators and Signaling Molecules
- •13.3.1.1 Response to Oxidative and Nitrosative Stress
- •13.3.1.2 Response to Altered Proteostasis
- •13.3.1.3 Response to Glutamate
- •13.3.1.4 Other Initiators
- •13.3.2 Signal Transducers, Intracellular Messengers and Upstream Elements
- •13.3.2.2 Small GTPases
- •13.3.3 Intracellular Signaling Cascades
- •13.3.3.1 Mitogen Activated Protein Kinases (MAPK) Pathway
- •13.3.3.2 PI3K/Akt Pathway
- •13.3.3.4 Unfolded Protein Response (UPR)
- •13.3.4 Potentially Involved Intracellular Signaling Components
- •13.3.4.3 PINK1
- •13.3.5.2 Dopamine Metabolism
- •13.3.5.3 Cell Cycle
- •13.3.5.4 Autophagy
- •13.3.5.5 Apoptosis
- •13.4 Conclusions
- •References
- •Subject Index
Extracellular and Intracellular Signaling
RSC Drug Discovery Series
Editor-in-Chief
Professor David Thurston, London School of Pharmacy, UK
Series Editors:
Dr David Fox, Pfizer Global Research and Development, Sandwich, UK
Professor Salvatore Guccione, University of Catania, Italy
Professor Ana Martinez, Instituto de Quimica Medica-CSIC, Spain Dr David Rotella, Montclair State University, USA
Advisor to the Board:
Professor Robin Ganellin, University College London, UK
Titles in the Series:
1:Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET
2:Emerging Drugs and Targets for Alzheimer’s Disease; Volume 1: BetaAmyloid, Tau Protein and Glucose Metabolism
3:Emerging Drugs and Targets for Alzheimer’s Disease; Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies
4:Accounts in Drug Discovery: Case Studies in Medicinal Chemistry
5:New Frontiers in Chemical Biology: Enabling Drug Discovery
6:Animal Models for Neurodegenerative Disease
7:Neurodegeneration: Metallostasis and Proteostasis
8:G Protein-Coupled Receptors: From Structure to Function
9:Pharmaceutical Process Development: Current Chemical and Engineering Challenges
10:Extracellular and Intracellular Signaling
How to obtain future titles on publication:
A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.
For further information please contact:
Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK
Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247, Email: books@rsc.org Visit our website at http://www.rsc.org/Shop/Books/
Extracellular and Intracellular
Signaling
Edited by
James D. Adams, Jr.
School of Pharmacy, University of Southern California, Los Angeles, CA, USA
Keith K. Parker
Department of Biomedical and Pharmaceutical Sciences (BMED), Skaggs School of Pharmacy and Allied Health Sciences, University of Montana, Missoula, MT, USA
RSC Drug Discovery Series No. 10
ISBN: 978-1-84973-160-7
ISSN: 2041-3203
A catalogue record for this book is available from the British Library
r Royal Society of Chemistry 2011
All rights reserved
Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.
The RSC is not responsible for individual opinions expressed in this work.
Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK
Registered Charity Number 207890
For further information see our website at www.rsc.org
Preface
‘‘The ten thousand things carry yin and embrace yang. They achieve harmony by combining these forces.’’
Lao Tzu from the ‘‘Tao Te Ching’’
Keith Parker and I were graduate students in the laboratory of Anthony Trevor at the University of California San Francisco. We studied Pharmacology diligently and were lucky enough to be taught by Dr. Trevor, who is one of the best teachers and a great mentor. The most important concept we learned from him was to be open minded. As we learned about diseases, I became aware that the causes of many diseases were not known, such as diabetes, arthritis, cardiovascular disease, congestive heart failure and other chronic diseases.
I had been fortunate to be taught the Science of Entomology by my father, James David Adams, PhD. On many hikes, he taught me to be open minded and to be ready to go where the data lead. It is after all the data that are important. The hypothesis must change as new data become available.
I married Linda Mei, who taught me to speak Cantonese. I learned about Chinese culture, history, language and medicine. Our son, Elliott Trevor Adams, has given me the opportunity to take him on hikes and explain science to him.
At the University of Southern California, I collaborate with Eric Lien, and am greatly expanding my understanding of Chinese medicine. It was due to his influence that I began to try to describe Chinese medical theory in terms of western scientific mechanisms.
I became the student of Cecilia Garcia, a Chumash Indian healer. She taught me that healing and disease prevention are the first priorities in medicine. I continue to be challenged to find scientific mechanisms to describe American Indian healing.
RSC Drug Discovery Series No. 10 Extracellular and Intracellular Signaling
Edited by James D. Adams, Jr. and Keith K. Parker r Royal Society of Chemistry 2011
Published by the Royal Society of Chemistry, www.rsc.org
v
vi |
Preface |
This book demonstrates how much science has advanced in the understanding of the causes of diseases and how both intracellular and extracellular signaling are involved. A balance between these signaling cascades is required for health and disease prevention. The concept of balance in health is more than 2000 years old in Chinese medicine, and at least as old in American Indian medicine. This book attempts to give scientific mechanisms that explain the necessity of balance in health.
James David Adams, Jr., PhD
Associate Professor of Pharmacology and Pharmaceutical Sciences University of Southern California, School of Pharmacy Los Angeles, California, USA
This book is jointly edited by Jim Adams and myself, but there is no doubt that the book’s inspiration came from Jim. I am most grateful to Jim for his invitation to join him in this endeavor, and his vision and drive to bring the book into reality has been instrumental to all of us as contributors! After stints in graduate school and post-doctoral research, I envisioned the move back to my home state of Montana in 1981. It was at this time that I began to appreciate the contributions to medicine and health made by native peoples. The holistic themes of this book resonate well with me in that context and, hopefully, such blending of multiple approaches will continue to increase.
As with any project, there are debts to many, and I hope to acknowledge a few of those here. My wife Julie’s and the entire family’s love, dedication and patience are without parallel. I cannot thank them enough. As Jim did, I would also like to thank Tony Trevor; his brilliance as a scientist and his personal confidence in us has been immensely influential. Other mentors that I would like to note are: Pierce Mullen of Montana State University for his continuing friendship; Frank Tikalsky formerly of the Los Alamos National Laboratory for his infinite wisdom and his persistence in showing the wonders of native cultures; Antonia Vernadakis, a true pioneer in the field of glial research; and Eric Wickstrom of the Thomas Je erson Medical College, for his humanity and creativity. Of special note in this regard is Mike Norenberg of the University of Miami’s Miller School of Medicine. Mike’s willingness to write a chapter in the book is deeply appreciated and a unique plus for me and the readers. In these years back in Montana my colleagues throughout the state but especially at the Dillon (Western) and Missoula campuses of the University of Montana have been infinitely supportive and encouraging. In every sense, this book is truly a collaborative e ort!
Keith Krom Parker
Missoula
Montana
USA
Contents
Chapter 1 Extracellular and Intracellular Signaling – a New Approach |
|
|
to Diseases and Treatments |
1 |
|
James David Adams, Jr., Eric J. Lien and Keith Parker |
|
|
1.1 |
Introduction |
1 |
|
1.1.1 Linear Model of Drug Receptor Interactions |
1 |
|
1.1.2 Matrix Model of Drug Receptor Interactions |
2 |
1.2 |
Experimental Approaches to Disease Treatment |
3 |
1.3 |
Adipokines and Disease Causation |
4 |
1.4 |
Questions in Disease Treatment |
6 |
1.5 |
Toxic Lifestyles and Disease Treatment |
7 |
References |
9 |
Chapter 2 Autocrine E ects in White Adipose Tissue and Pancreatic Islets: Emergent Roles in the Regulation of Adipocyte and
Pancreatic b-cell Function 10
Mary C. Sugden and Mark J. Holness
2.1 Introduction |
10 |
2.2Heterogeneity of Adipose Tissue Composition in
|
Relation to Adipokine and Cytokine Secretion |
11 |
2.3 |
Feedback between FA and the Adipocyte |
14 |
2.4 |
Autocrine E ects of Leptin and Adiponectin |
|
|
in Adipocytes |
15 |
2.5Potential E ects of PPARa Deficiency on Autocrine
Signaling in Adipose Tissue |
17 |
RSC Drug Discovery Series No. 10 Extracellular and Intracellular Signaling
Edited by James D. Adams, Jr. and Keith K. Parker r Royal Society of Chemistry 2011
Published by the Royal Society of Chemistry, www.rsc.org
vii
viii |
Contents |
2.6Metabolic Programming of Autocrine Signaling
in Adipose Tissue |
19 |
2.7Autocrine E ects on Adipose Tissue Could Modulate
|
the Operation of the Adipocyte Circadian Clock |
20 |
2.8 |
Cell Heterogeneity in the Pancreatic Islet |
21 |
2.9 |
Autocrine E ects of Insulin on the Pancreatic |
|
|
b Cell |
22 |
2.10Is Early Life Programming of Insulin Resistance by
Altered Insulin Signaling Accompanied by an |
|
Abnormal Autocrine E ect of Insulin on the |
|
Pancreatic b Cell? |
25 |
2.11 E ects of FA on the Pancreatic b cell |
26 |
2.12E ects of Leptin and Adiponectin on the Pancreatic
b Cell |
27 |
2.13 E ects of TNFa on the b Cell |
29 |
2.14Is Programmed Obesity Associated with b-cell
Inflammation? |
29 |
2.15Other Adipose-derived Factors that Could
Contribute to the Adipoinsular Axis |
30 |
2.16 Concluding Remarks |
32 |
Acknowledgements |
32 |
References |
32 |
Chapter 3 One Receptor for Multiple Pathways: Focus on Leptin
Signaling 44
Rodolfo Go´mez, Javier Conde, Morena Scotece and Oreste Gualillo
3.1 |
Leptin |
|
44 |
3.2 |
Leptin Receptors |
45 |
|
3.3 |
Leptin Receptor Signaling |
45 |
|
|
3.3.1 |
The JAK2-STATs Routes |
45 |
|
3.3.2 |
ERK1/2 |
48 |
|
3.3.3 |
PI3K/AKT |
49 |
|
3.3.4 |
AMPK |
49 |
|
3.3.5 |
SOCS3 |
50 |
3.4 |
Leptin |
Receptor Interactions |
50 |
|
3.4.1 |
Apolipoprotein D |
51 |
|
3.4.2 |
Sorting Nexin Molecules |
51 |
|
3.4.3 |
Diacylglycerol Kinase Zeta |
51 |
|
3.4.4 |
Apolipoprotein J |
52 |
References |
|
52 |
Contents |
|
|
ix |
Chapter 4 Cell Signaling Mechanisms Underlying the Cardiac Actions |
|
||
of Adipokines |
57 |
||
Morris Karmazyn and Venkatesh Rajapurohitam |
|
||
4.1 |
Introduction |
57 |
|
4.2 |
Leptin: A Brief Introduction |
58 |
|
4.3 |
Expression of Leptin Receptors in Cardiovascular |
|
|
|
Tissues |
58 |
|
4.4 |
E ect of Leptin on Cardiomyocyte Function |
59 |
|
4.5 |
Cardiomyocyte Hypertrophic E ects of Leptin |
59 |
|
4.6 |
Post Receptor Leptin Signaling |
61 |
|
|
4.6.1 |
JAK-STAT Pathway Activation |
61 |
|
4.6.2 Mitogen Activated Protein Kinase Stimulation |
62 |
|
|
4.6.3 Pivotal Role for the RhoA/ROCK System in |
|
|
|
|
Mediating the Hypertrophic E ects of Leptin |
63 |
4.7 |
Adiponectin |
63 |
|
|
4.7.1 Adiponectin and Cardiovascular Disease |
64 |
|
|
4.7.2 Adiponectin and Experimental Cardiac |
|
|
|
|
Hypertrophy |
64 |
|
4.7.3 Cell Signaling Mechanisms Underlying |
|
|
|
|
Cardioprotective and Antihypertrophic |
|
|
|
E ects of Adiponectin |
65 |
4.8 |
Resistin |
66 |
|
|
4.8.1 Cardiac Actions of Resistin |
67 |
|
4.9 |
Apelin |
67 |
|
|
4.9.1 Apelin and Heart Disease |
68 |
|
4.10 |
Visfatin |
68 |
|
4.11 |
Other Novel Adipokines |
69 |
|
4.12 |
Summary, Conclusions and Future Directions |
70 |
|
Acknowledgements |
70 |
||
References |
|
70 |
|
Chapter 5 Regulation of Muscle Proteostasis via Extramuscular Signals |
77 |
||
Philip J. Atherton and Nathaniel J. Szewczyk |
|
||
5.1 |
Basic Protein Synthesis |
77 |
|
5.2 The E ects of Extramuscular Signals on Global |
|
||
|
Proteostasis in Muscle |
79 |
|
|
5.2.1 |
Hormones |
79 |
|
5.2.2 |
Local Factors (Autocrine/Paracrine) |
82 |
5.3 Regulation of Muscle Proteostasis in Humans |
88 |
||
|
5.3.1 Nutrients as Regulators of Muscle Proteostasis |
|
|
|
|
in Man |
89 |
|
5.3.2 Muscular Activity (i.e. Exercise) as a Regulator |
|
|
|
|
of Muscle Proteostasis |
92 |
x |
|
|
Contents |
5.4 |
Conditions Associated with Alterations in Muscle |
|
|
|
Proteostasis in Humans |
95 |
|
|
5.4.1 E ects of Aging on Muscle Proteostasis |
96 |
|
|
5.4.2 |
Disuse Atrophy |
97 |
|
5.4.3 |
Sepsis |
99 |
|
5.4.4 |
Burns |
100 |
|
5.4.5 |
Cancer Cachexia |
101 |
References |
|
102 |
|
Chapter 6 Contact Normalization: Mechanisms and Pathways |
|
||
to Biomarkers and Chemotherapeutic Targets |
105 |
||
Jhon Alberto Ochoa-Alvarez, Candacy George, Harini |
|
||
Krishnan, Xiaoxuan Wu and Gary S. Goldberg |
|
||
6.1 |
Introduction |
105 |
|
6.2 |
Contact Normalization |
106 |
|
6.3 |
Cadherins |
106 |
|
6.4 |
Gap Junctions |
107 |
|
6.5 |
Contact Normalization and Tumor Suppressors |
108 |
|
6.6 |
Contact Normalization and Tumor Promoters |
109 |
|
6.7 |
Conclusions |
110 |
|
References |
|
110 |
|
Chapter 7 Involvement of Adipokines in Migraine Headache |
116 |
||
Keith K. Parker |
|
||
7.1 |
Introduction |
116 |
|
7.2 |
Background on Migraine Headache |
117 |
|
7.3 |
Migraine and Neuropathic Pain |
119 |
|
7.4 |
Role of Astrocytes in Pain |
121 |
|
7.5 |
Adipokines and Related Extracellular Signalling |
122 |
|
7.6 |
The Future of Signaling Research to Migraine |
125 |
|
Acknowledgements |
125 |
||
References |
|
125 |
|
Chapter 8 Adipokines and Alzheimer’s Disease |
130 |
||
Maria Angela Sortino, Sara Merlo and Simona Spampinato |
|||
8.1 |
Alzheimer’s Disease |
130 |
|
|
8.1.1 |
b-Amyloid and Tau |
131 |
|
8.1.2 Target for AD Therapy |
133 |
|
8.2 |
AD and Metabolic Dysfunction |
134 |
|
|
8.2.1 |
Impaired Glucose Metabolism |
134 |
|
8.2.2 |
Lipid Disorders |
135 |
|
8.2.3 |
Obesity |
136 |
Contents |
|
|
xi |
8.3 |
Adipokines |
136 |
|
|
8.3.1 |
Leptin |
137 |
|
8.3.2 |
Adiponectin |
139 |
|
8.3.3 |
Resistin |
139 |
|
8.3.4 |
Visfatin |
140 |
|
8.3.5 |
Plasminogen Activator Inhibitor |
140 |
|
8.3.6 |
Interleukin-6 |
141 |
|
8.3.7 |
Transforming Growth Factor-b1 |
141 |
8.4 |
Conclusions |
142 |
|
References |
|
142 |
|
Chapter 9 Astrocyte Signaling in Neurological Disorders |
149 |
||
A. R. Jayakumar and M. D. Norenberg |
|
||
9.1 |
Introduction |
149 |
|
|
9.1.1 |
Structure and Function of Astrocytes |
149 |
|
9.1.2 |
Responses of Astrocytes to Injury |
151 |
9.2 Intracellular Signaling System in Reactive Astrocytes |
155 |
||
|
9.2.1 |
Oxidative/Nitrosative Stress (ONS) |
155 |
|
9.2.2 |
Protein Kinase C (PKC) |
156 |
|
9.2.3 |
Phosphatidylinositol 3-Kinases (PI3K) |
156 |
|
9.2.4 |
Mitogen-activated Protein Kinases (MAPKs) |
156 |
|
9.2.5 |
Signal Transducer and Activator |
|
|
|
of Transcription 3 (STAT3) |
157 |
|
9.2.6 |
Nuclear Factor Kappa B (NF-kB) |
158 |
9.3 Signaling Systems in Astrocyte Swelling |
158 |
||
|
9.3.1 |
Oxidative/Nitrosative Stress (ONS) |
159 |
|
9.3.2 |
Cytokines |
159 |
|
Signaling Kinases |
160 |
|
|
9.3.3 |
Protein Kinase C (PKC) |
160 |
|
9.3.4 |
Phosphatidylinositol 3-Kinase (PI3K) |
160 |
|
9.3.5 |
Protein Kinase G (PKG) |
160 |
|
9.3.6 |
Mitogen-activated Protein Kinases (MAPKs) |
161 |
|
Transcription Factors |
161 |
|
|
9.3.7 |
Signal Transducer and Activator |
|
|
|
of Transcription 3 (STAT3) |
161 |
|
9.3.8 |
Nuclear Factor Kappa B (NF-kB) |
161 |
|
9.3.9 |
p53 |
162 |
|
Swelling E ectors |
162 |
|
|
9.3.10 |
Ion Channels/Transporters/Exchangers |
162 |
|
9.3.11 |
Aquaporin-4 (AQP-4) |
163 |
9.4 |
Conclusions and Perspectives |
163 |
|
Acknowledgements |
165 |
||
References |
|
165 |
xii |
|
Contents |
|
Chapter 10 DNA, Nuclear Cell Signaling and Neurodegeneration |
175 |
||
James D. Adams, Jr., Ph.D. |
|
||
10.1 |
Adipokines, Toxic Lipids and the Aging Brain |
175 |
|
|
10.1.1 Toxic Lifestyles, Adipokines and Toxic Lipids |
176 |
|
|
10.1.2 Ceramide Toxicity in the Brain |
177 |
|
|
10.1.3 Endocannabinoids, Ceramide and Amyloidb |
177 |
|
10.2 |
The Blood-Brain Barrier as a Target |
|
|
|
for Neurodegenerative Conditions |
178 |
|
|
10.2.1 Visfatin and the Blood-Brain Barrier |
178 |
|
10.3 |
Oxygen Radicals, Hydrogen Peroxide and Cell Death |
179 |
|
10.4 |
Gene Transcription and DNA Damage |
183 |
|
10.5 |
Conclusions |
184 |
|
References |
|
184 |
|
Chapter 11 G Protein-Coupled Receptors: Conformational |
|
||
‘‘Gatekeepers’’ of Transmembrane Signal Transduction |
|
||
and Diversification |
188 |
||
Ravinder Abrol and William A. Goddard III, FRSC |
|
||
11.1 |
Introduction |
188 |
|
11.2 |
Cellular Signaling |
190 |
|
|
11.2.1 |
Types of Signaling |
190 |
|
11.2.2 Membrane Proteins in Signaling |
191 |
|
11.3 |
G Protein-Coupled Receptors |
192 |
|
|
11.3.1 |
Structure of GPCRs |
193 |
|
11.3.2 GPCR Activation: Conformation Driven |
|
|
|
|
Functional Selectivity |
203 |
|
11.3.3 Functional Control of GPCRs by Ligands |
217 |
|
|
11.3.4 Challenges in GPCR Targeted Drug Design |
221 |
|
11.4 |
Summary and Looking Ahead |
223 |
|
Acknowledgements |
224 |
||
References |
|
225 |
|
Chapter 12 Phytochemicals as Modulators of Signaling in Inflammation |
230 |
||
Lori Klaidman |
|
|
|
12.1 |
Introduction |
230 |
|
12.2 |
Overview of the Inflammatory Cascade |
231 |
|
12.3 |
Overview of NF-kB |
232 |
|
12.4 |
PPARg and LXRs Regulate NF-kB |
233 |
|
12.5 |
Natural Products and Phytochemical |
|
|
|
Inhibitors of NF-kB |
235 |
|
|
12.5.1 |
Anthocyanins |
235 |
|
12.5.2 |
Gallates |
236 |
Contents |
xiii |
|
12.5.3 |
Quercetin |
237 |
|
12.5.4 |
Isoflavones |
237 |
|
12.5.5 |
Piperine |
238 |
|
12.5.6 |
Gingerol |
239 |
|
12.5.7 |
Curcumin |
239 |
|
12.5.8 |
Guggulsterone |
240 |
12.6 |
Agonists of PPARg that Reciprocally Inhibit NF-kB |
241 |
|
|
12.6.1 |
Phytanic Acid |
241 |
|
12.6.2 |
Dehydroabietic Acid |
241 |
|
12.6.3 |
Geraniol |
242 |
12.7 |
Agonists of LXR that Reciprocally Inhibit NF-kB |
242 |
|
|
12.7.1 |
Stigmasterol |
242 |
|
12.7.2 |
b-Sitosterol |
243 |
|
12.7.3 |
Ergosterol |
243 |
12.8 |
Conclusion |
243 |
|
References |
|
244 |
|
Chapter 13 Intracellular Signaling Pathways in Parkinson’s Disease |
247 |
||
Monica Sanchez Contreras and Fernando Cardozo-Pelaez |
|
||
13.1 |
Introduction |
247 |
|
13.2 |
Selective Dopaminergic Neuronal Death |
248 |
|
13.3 |
Signaling Pathways Involved in Selective |
|
|
|
Dopaminergic Neuronal Death |
254 |
|
|
13.3.1 Initiators and Signaling Molecules |
254 |
|
|
13.3.2 Signal Transducers, Intracellular Messengers |
|
|
|
|
and Upstream Elements |
261 |
|
13.3.3 |
Intracellular Signaling Cascades |
263 |
|
13.3.4 Potentially Involved Intracellular Signaling |
|
|
|
|
Components |
266 |
|
13.3.5 E ector Pathways and Final E ects |
267 |
|
13.4 |
Conclusions |
270 |
|
References |
|
271 |
|
Subject Index |
|
|
283 |